Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

Josh H. Heinzerling, MD
Published Online: Tuesday, Nov 21, 2017



Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.

According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.
 


Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

There is a lot of work to do in earlier stages of disease, states Heinzerling. As CT screening is being adopted nationwide, more work will need to be done as this is going to shift the patient spectrum from stage IV disease to stage I, II, or III disease.

According to Heinzerling, the hope is there will be early-stage treatments and better cure rates.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x